TroVax Renal Immunotherapy Survival Trial
Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma.
Sponsor: Oxford BioMedica
A PHASE3 clinical study on Clear Cell Renal Carcinoma, this trial is completed. The trial is conducted by Oxford BioMedica and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Oxford BioMedica
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abingdon, United States , Arad, Romania , Arkhangelsk, Russia , Augusta, United States , Aurora, United States , Barakaldo, Spain , Barcelona, Spain , Bebington, United Kingdom , Belfast, United Kingdom , Besançon, France and 108 more locations